This data strengthens SGT-003's differentiation and supports potential for accelerated approval. Traders should monitor upcoming FDA meetings in H1 2026 for guidance on accelerated approval pathway and mid-2026 clinical updates.
Price Chart
Executive Summary
Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing robust microdystrophin expression and biomarker improvements in Duchenne muscular dystrophy patients. The company also confirmed FDA alignment on the Phase 3 IMPACT DUCHENNE trial design, with dosing expected to begin in Q1 2026.
Key Facts
- SGT-003 showed 60% mean microdystrophin expression by western blot at Day 90 (n=19), increasing to 91% at Day 360 (n=3)
- Mean vector copies per nucleus were 11 at Day 90 and 12 at Day 360, indicating stable transduction
- Key biomarkers showed significant improvement: 38% mean reduction in serum creatine kinase (CK) at Day 90, 44% reduction in eMHC-positive fibers suggesting disruption of degeneration-regeneration cycle
- FDA has agreed the Phase 3 IMPACT DUCHENNE trial design is reasonable, with dosing expected in Q1 2026
- SGT-003 is the only microdystrophin therapy with the R16/R17 binding domain that localizes nNOS to muscle
Financial Impact
No direct financial impact disclosed, but clinical progress significantly de-risks development path for SGT-003
Risk Factors
- Interim data from small samples (n=3 at Day 360) may not be predictive of final outcomes
- Phase 3 trial results may not replicate Phase 1/2 findings
- Company remains dependent on raising substantial additional capital to continue development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-102489 |
| Document: 0001193125-26-102489-index-headers.html | 0001193125-26-102489 |
| Document: 0001193125-26-102489-index.html | 0001193125-26-102489 |
| Document: 0001193125-26-102489.txt | 0001193125-26-102489 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | S-3ASR | $8.39 $10.25 | ▲ +22.17% | ▲ +22.57% | $6.85 (−18.36%) |
May 12, 2026 20w ago | Press Release | $7.38 $7.22 | ▲ +2.17% | ▲ +1.56% | $6.85 (+7.18%) |
May 7, 2026 21w ago | Press Release | $7.07 $6.85 | ▼ −3.11% | ▼ −6.25% | $6.85 (−3.11%) |
Apr 23, 2026 23w ago | DEFA14A | $7.92 $6.50 | ▼ −17.93% | ▼ −21.96% | $6.85 (−13.51%) |
Apr 10, 2026 25w ago | 8-K | $8.39 $7.68 | ▼ −8.46% | ▼ −16.19% | $6.85 (−18.36%) |
Apr 1, 2026 26w ago | EFFECT | $7.38 $7.05 | ▲ +4.47% | ▲ +14.19% | $6.85 (+7.18%) |
Mar 19, 2026 28w ago | Press Release | $7.03 $8.49 | ▲ +20.77% | ▲ +11.45% | $6.85 (−2.56%) |
Mar 12, 2026 29w ago | 8-K | $7.71 $8.02 | ▲ +4.02% | ▲ +2.05% | $6.85 (−11.15%) |
Mar 11, 2026 29w ago | Press Release | $7.72 $8.10 | ▲ +4.99% | ▲ +4.47% | $6.85 (−11.21%) |
Mar 6, 2026 30w ago | Press Release | $6.75 $7.74 | ▲ +14.67% | ▲ +16.71% | $6.85 (+1.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access